SCHEDULE: FMR LLC Discloses 8.7% Stake in arGEN-X SE

FMR LLC, through its subsidiaries and affiliates, has reported beneficial ownership of 8.7% of arGEN-X SE's common stock as of March 31, 2026.

Summary

• FMR LLC, along with its subsidiaries and affiliates (collectively, the "FMR Reporters"), has filed a Schedule 13G, indicating a significant beneficial ownership in arGEN-X SE.
• As of March 31, 2026, FMR LLC beneficially owns 5,409,597.24 shares of arGEN-X SE's common stock.
• This ownership represents 8.7% of the total outstanding common stock of arGEN-X SE.
• FMR LLC holds sole dispositive power over these shares and has shared voting power of 0.00.
• Abigail P. Johnson, Director, Chairman, and CEO of FMR LLC, is also noted as a significant owner through family trusts, potentially forming a controlling group with respect to FMR LLC.
• The filing clarifies that this report does not include securities beneficially owned by certain other companies whose ownership is disaggregated from the FMR Reporters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine ownership disclosure and does not provide new operational or financial information about arGEN-X SE.

Positives

• FMR LLC's substantial stake of 8.7% indicates significant investor confidence in arGEN-X SE.
• The clear reporting of beneficial ownership provides transparency to the market regarding major shareholders.

Negatives

• The filing does not contain financial performance data or operational updates for arGEN-X SE, focusing solely on ownership disclosure.

Risks

• Potential for future changes in FMR LLC's ownership stake, which could impact arGEN-X SE's stock price.
• The influence of Abigail P. Johnson and the Johnson family group on FMR LLC's voting decisions could be a factor in corporate governance.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding arGEN-X SE's future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as disclosed by FMR LLC, is a common indicator of investor interest in biotechnology companies like arGEN-X SE, which are often subject to substantial investment and development risks and rewards.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's holdings, potentially influencing market perception.
• Management of arGEN-X SE: Awareness of a substantial shareholder's position and potential influence.
• Competitors: Information on major investment players in the biotechnology sector.

Next Steps

• FMR LLC will continue to report any material changes in its beneficial ownership of arGEN-X SE's common stock.
• arGEN-X SE is expected to continue its operations and disclosures as per regulatory requirements.

Key Dates

Keywords

arGEN-X SE, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Shareholder, SEC Filing, Biotechnology